SLN
Silence Therapeutics PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$276.32M
P/E Ratio
—
EPS
$-1.89
Beta
1.33
52W High
$7.91
52W Low
$2.21
50-Day MA
$5.46
200-Day MA
$5.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, is focused on the discovery and development of new ribonucleic acid (RNA) therapies in hematology, cardiovascular, and other rare and metabolic indications. The company is headquartered in London, the United Kingdom.
Fundamentals
| Revenue (TTM) | 559,000 |
| Gross Profit (TTM) | 344,000 |
| EBITDA | $-81.73M |
| Operating Margin | -37150.00% |
| Return on Equity | -90.30% |
| Return on Assets | -30.80% |
| Revenue/Share (TTM) | $0.01 |
| Book Value | $1.32 |
| Price-to-Book | 4.50 |
| Price-to-Sales (TTM) | 494.31 |
| EV/Revenue | 355.01 |
| EV/EBITDA | -5.78 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -99.90% |
| Shares Outstanding | $47.23M |
| Float | $74.75M |
| % Insiders | 24.38% |
| % Institutions | 39.90% |
Analyst Ratings
Consensus ($32.80 target)
1
Strong Buy4
Buy1
SellData last updated: 4/9/2026